Ergoteles’s Viking Therapeutics VKTX Stock Holding History

Ergoteles’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-198,164	Closed	-$539K	–	1919
2022 Q3	$539K	Sell	198,164 -132,336	-40%	-$433K	0.02%	728
2022 Q2	$955K	Buy	+330,500	New	+$818K	0.03%	560

Other funds holding VKTX

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ergoteles's VKTX Position: Q4 2022 in Review

Ergoteles sold out of Viking Therapeutics (VKTX) in Q4 2022, closing a stake of 198,164 shares — an estimated $539K sold.

Ergoteles first reported a position in VKTX in Q2 2022 and held it in 2 quarters. The position peaked at $955K in Q2 2022. 129 funds tracked by Wall St. Rank hold VKTX as of Q4 2022.

Ergoteles reported no remaining Viking Therapeutics position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 198,164 Viking Therapeutics shares in Q4 2022, an estimated $539K.
Ergoteles first reported a position in Viking Therapeutics in Q2 2022 and held it in 2 quarters.
Ergoteles's Viking Therapeutics position peaked at $955K in Q2 2022.
129 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.